Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 19/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | BCHE | P06276 | 15/20 | 0.72 |
| ▸ | GRIN1 | Q05586 | 15/20 | 0.72 |
| ▸ | GRIN2A | Q12879 | 15/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29817833 | 0.84 | ACHE (1.00) | ACHEBCHEGRIN1GRIN2A | |
| SCHEMBL8018131 | 0.84 | ACHE (1.00) | ACHEBCHEGRIN1GRIN2A | |
| SCHEMBL30397413 | 0.84 | ACHE (1.00) | ACHEBCHEGRIN1GRIN2A | |
| SCHEMBL28998722 | 0.84 | ACHE (1.00) | ACHEBCHEGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL29817663 | 0.83 | ACHE (1.00) | ACHEBCHEGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL29817805 | 0.83 | ACHE (1.00) | ACHEBCHEGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL29818018 | 0.83 | ACHE (1.00) | ACHEBCHEGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL29817806 | 0.83 | ACHE (1.00) | ACHEBCHEGRIN1GRIN2A | |
| SCHEMBL8006170 | 0.82 | ACHE (1.00) | ACHEBCHEGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL29817798 | 0.81 | ACHE (1.00) | ACHEBCHEGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060030565-A1 | Amide derivatives and nociceptin antagonists | JAPAN TOBACCO INC. | 2006-02-09 | — | — | US | disclosed |
| US-6903094-B2 | Amide derivatives and nociceptin antagonists | JAPAN TABACCO, INC. (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20030055087-A1 | Amide derivatives and nociceptin antagonists | JAPAN TOBACCO INC. | 2003-03-20 | — | — | US | disclosed |
| US-6410561-B1 | ANALGESICS | JAPAN TOBACCO INC. (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1072263-A1 | AMIDE DERIVATIVES AND NOCICEPTIN ANTAGONISTS | JAPAN TOBACCO INC. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055087-A1 | Amide derivatives and nociceptin antagonists | OPRL1, OPRD1, OPRK1 | ACHE 298/4885MAPT 3992/4885BCHE 1579/4885 |
| US-20060030565-A1 | Amide derivatives and nociceptin antagonists | OPRL1, OPRD1, OPRM1 | ACHE 214/4885MAPT 4000/4885BCHE 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.